Impact of tumor-treating fields on the survival of Japanese patients with newly diagnosed glioblastoma: A multicenter, retrospective cohort study

被引：0

作者：

Kanamori, Masayuki ^{[1
]}

Tsuzuki, Shunsuke ^{[2
]}

Shibahara, Ichiyo ^{[3
]}

Saito, Kuniaki ^{[4
]}

Shimoda, Yoshiteru ^{[1
]}

Tanaka, Kazuhiro ^{[5
]}

Yamaguchi, Shigeru ^{[6
]}

Natsumeda, Manabu ^{[7
]}

Matsutani, Tomoo ^{[8
]}

Hanihara, Mitsuto ^{[9
]}

Nakada, Mitsutoshi ^{[10
]}

Kuroda, Jun-Ichiro ^{[11
]}

Matsuda, Masahide ^{[12
]}

Yoshimoto, Koji ^{[13
]}

Yonezawa, Ushio ^{[14
]}

Sonoda, Yukihiko ^{[15
]}

Takano, Koji ^{[16
]}

Yonezawa, Hajime ^{[17
]}

Otani, Yoshihiro ^{[18
]}

Nakahara, Yukiko ^{[19
]}

Uchida, Masashi ^{[20
]}

Nonaka, Masahiro ^{[21
]}

Mineharu, Yohei ^{[22
]}

Kitamura, Yohei ^{[23
]}

Yamashita, Shinji ^{[24
]}

Yamauchi, Takahiro

Miyake, Yohei ^{[26
]}

Deguchi, Shoichi ^{[27
]}

Beppu, Takaaki ^{[28
]}

Tamura, Kaoru ^{[29
]}

Koizumi, Shinichiro ^{[30
]}

Hirose, Yuichi ^{[31
]}

Asano, Kenichiro ^{[32
]}

Hiruta, Ryo ^{[33
]}

Kinoshita, Manabu ^{[34
]}

Miyake, Keisuke ^{[35
]}

Nakayama, Noriyuki ^{[36
]}

Inoue, Akihiro ^{[37
]}

Ono, Takahiro ^{[38
]}

Sasaki, Takahiro ^{[39
]}

Akiyama, Yukinori ^{[40
]}

Fukami, Shinjiro ^{[41
]}

Yoshino, Atsuo ^{[42
]}

Kawanishi, Yu ^{[43
]}

Asanome, Taku ^{[44
]}

Yamaguchi, Takuhiro ^{[25
,45
]}

Takahashi, Masamichi ^{[46
]}

Yamasaki, Fumiyuki ^{[14
]}

Arakawa, Yoshiki ^{[22
]}

Narita, Yoshitaka ^{[46
]}

机构：

[1] Tohoku Univ, Grad Sch Med, Dept Neurosurg, 1-1 Seiryo Cho,Aoba Ku, Sendai, Japan

[2] Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan

[3] Kitasato Univ, Sch Med, Dept Neurosurg, Sagamihara, Japan

[4] Kyorin Univ Facil Med, Dept Neurosurg, Tokyo, Japan

[5] Kobe Univ, Grad Sch Med, Dept Neurosurg, Kobe, Japan

[6] Hokkaido Univ, Fac Med, Dept Neurosurg, Sapporo, Japan

[7] Niigata Univ, Brain Res Inst, Dept Neurosurg, Niigata, Japan

[8] Chiba Univ, Grad Sch Med, Dept Neurol Surg, Chiba, Japan

[9] Univ Yamanashi, Dept Neurosurg, Yamanashi, Japan

[10] Kanazawa Univ, Dept Neurosurg, Kanazawa, Japan

[11] Kumamoto Univ, Fac Life Sci, Dept Neurosurg, Kumamoto, Japan

[12] Univ Tsukuba, Inst Med, Dept Neurosurg, Tsukuba, Japan

[13] Kyushu Univ, Grad Sch Med Sci, Dept Neurosurg, Fukuoka, Japan

[14] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan

[15] Yamagata Univ, Fac Med, Dept Neurosurg, Yamagata, Japan

[16] Osaka Int Canc Inst, Dept Neurosurg, Osaka, Japan

[17] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurosurg, Kagoshima, Japan

[18] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg, Okayama, Japan

[19] Saga Univ, Fac Med, Dept Neurosurg, Saga, Japan

[20] St Marianna Univ, Sch Med, Dept Neurosurg, Kawasaki, Kanagawa, Japan

[21] Kansai Med Univ, Dept Neurosurg, Hirakara, Japan

[22] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto, Japan

[23] Keio Univ, Sch Med, Dept Neurosurg, Tokyo, Japan

[24] Univ Miyazaki, Fac Med, Dept Clin Neurosci, Div Neurosurg, Miyazaki, Japan

[25] Univ Fukui, Fac Med Sci, Dept Neurosurg, Div Med, Fukui, Japan

[26] Yokohama City Univ, Grad Sch Med, Dept Neurosurg, Yokohama, Japan

[27] Shizuoka Canc Ctr, Div Neurosurg, Nagaizumi, Japan

[28] Iwate Med Univ, Dept Neurosurg, Shiwa, Japan

[29] Tokyo Med & Dent Univ, Dept Neurosurg, Tokyo, Japan

[30] Hamamatsu Univ, Sch Med, Dept Neurosurg, Hamamatsu, Japan

[31] Fujita Hlth Univ, Dept Neurosurg, Toyoake, Japan

[32] Hirosaki Univ, Grad Sch Med, Dept Neurosurg, Hirosaki, Japan

[33] Fukushima Med Univ, Dept Neurosurg, Fukushima, Japan

[34] Asahikawa Med Univ, Dept Neurosurg, Asahikawa, Hokkaido, Japan

[35] Kagawa Univ, Fac Med, Dept Neurol Surg, Kagawa, Japan

[36] Gifu Univ, Grad Sch Med, Dept Neurosurg, Gifu, Japan

[37] Ehime Univ, Sch Med, Dept Neurosurg, Toon, Japan

[38] Akita Univ, Grad Sch Med, Dept Neurosurg, Akita, Japan

[39] Wakayama Med Univ, Sch Med, Dept Neurol Surg, Wakayama, Japan

[40] Sapporo Med Univ, Dept Neurosurg, Sapporo, Japan

[41] Tokyo Med Univ, Dept Neurosurg, Tokyo, Japan

[42] Nihon Univ, Sch Med, Dept Neurol Surg, Tokyo, Japan

[43] Kochi Univ, Kochi Med Sch, Dept Neurosurg, Kochi, Japan

[44] Nakamura Mem Hosp, Brain Tumor Ctr, Dept Neurosurg, Sapporo, Japan

[45] Tohoku Univ, Grad Sch Med, Div Biostat, Sendai, Japan

[46] Natl Canc Ctr, Dept Neurosurg & Neurooncol, Tokyo, Japan

来源：

NEURO-ONCOLOGY ADVANCES | 2024年 / 6卷 / 01期

关键词：

Asian population; determinant of use; glioblastoma; survival; tumor-treating fields; PHASE-II; TEMOZOLOMIDE; CHEMOTHERAPY; RESECTION; EFFICACY; CRITERIA; EXTENT; TRIAL; WAFER;

D O I：

10.1093/noajnl/vdae176

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. The EF-14 clinical trial demonstrated the safety and efficacy of tumor-treating fields (TTFields) for newly diagnosed glioblastoma. This study aimed to clarify the current status, safety, and efficacy of TTFields in Japanese patients who meet the EF-14 inclusion criteria. Methods. This was a multicenter retrospective cohort study. Background, treatment, and outcome data of patients who satisfied the inclusion criteria of the EF-14 trial were collected from 45 institutions across Japan. The rate, determinants, and current status of TTField use, including its safety and efficacy in terms of progression and survival, were retrospectively investigated. This study was conducted in accordance with the STROBE checklist. Results. Among the 607 patients enrolled, 70 were excluded due to progressive disease during radiation and temozolomide therapy, age > 80 years old, and Karnofsky Performance Status score of <70. Among the remaining 537 patients, 210 (39%) underwent TTField treatment. Multivariate analysis revealed younger age and spouse as a caregiver as significant factors for TTField use. The compliance rate of TTField use exceeded 75% in 60% of patients, with a median TTField usage duration of 11 months. Skin disorders requiring medical treatment occurred in 56% of patients. Multivariate Cox proportional hazards analysis in the whole series and propensity score-matched analysis revealed that TTField use was not a prognostic factor for progression-free survival (PFS) or overall survival (OS). Conclusions. TTField use did not have a substantial effect on either PFS or OS in Japanese patients with glioblastoma, despite compliance rates comparable to those observed in the EF-14.

引用

页数：11

共 50 条

[21] RETROSPECTIVE ANALYSIS OF USING RADIOTHERAPY WITH CONCURRENT TEMOZOLOMIDE AND TUMOR TREATING FIELDS FOR CHINESE PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Wang, Yang
Wu, Jingsong
Qin, Zhiyong
Wang, Enmin
Yao, Yu
Zhuang, Dongxiao
Liang, Lipin
Ni, Chunxia
Lu, Peijiang
Chen, Shu
Li, Chao
NEURO-ONCOLOGY, 2021, 23 : 72 - 72
[22] The impact of timing of temozolomide chemoradiotherapy for newly diagnosed glioblastoma on patient overall survival: A multicenter retrospective study
Lau, Arthur C. K.
Chan, Brandon L. H.
Yeung, Carly S. K.
Li, Lai-Fung
Chan, Danny T. M.
Lee, Michael W. Y.
Chan, Tony K. T.
Ho, Jason M. K.
Cheung, Ka-Man
Tse, Teresa P. K.
Lau, Sarah S. N.
Chow, Joyce S. W.
Ko, Natalie M. W.
Loong, Herbert H. F.
El-Helali, Aya
Poon, Wai-Sang
Woo, Peter Y. M.
NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
[23] Quality of Life in Patients With Glioblastoma Treated With Tumor-Treating Fields Reply
Stupp, Roger
Ram, Zvi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (17): : 1823 - 1823
[24] Early metabolic response to tumor-treating fields in patients with recurrent glioblastoma
Mittal, Sandeep
Barger, Geoffrey R.
Bosnyak, Edit
Shah, Varun B.
Juhasz, Csaba
CANCER RESEARCH, 2017, 77
[25] A LONGITUDINAL OBSERVATIONAL STUDY OF EXERCISE BEHAVIOR IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR-TREATING FIELDS
Peters, Katherine
Affronti, Mary
Kim, Jung-Young
Patel, Mallika
Johnson, Margaret
Bartlett, David
Cort, Nicole
Lipp, Eric
Iden, Deborah
Broadwater, Gloria
Herndon, James
Landi, Daniel
Khasraw, Mustafa
Desjardins, Annick
Friedman, Henry
Ashley, David M.
NEURO-ONCOLOGY, 2021, 23 : 184 - 185
[26] Safety of tumor treating fields and concomitant radiotherapy for newly diagnosed glioblastoma
Grossman, Rachel
Bukstein, Felix
Blumenthal, Deborah T.
Ben Harush, Carmit
Limon, Dror
Ram, Zvi
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[27] Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields
Aaron Michael Rulseh
Jiří Keller
Jan Klener
Jan Šroubek
Vladimír Dbalý
Martin Syrůček
František Tovaryš
Josef Vymazal
World Journal of Surgical Oncology, 10
[28] TUMOR-TREATING FIELDS COMBINED WITH SECOND-LINE CHEMOTHERAPY IN RECURRENT GLIOBLASTOMA: A MATCHED RETROSPECTIVE STUDY
Mou, Yonggao
Yang Qun-ying
Guo, Cheng-Cheng
Deng, Meiling
Chen, Yin-Sheng
Du, Xiao-Jing
Wu, Shao-xiong
Wang, Jian
Ke, Sai
NEURO-ONCOLOGY, 2021, 23 : 61 - 61
[29] Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields
Rulseh, Aaron Michael
Keller, Jiri
Klener, Jan
Sroubek, Jan
Dbaly, Vladimir
Syrucek, Martin
Tovarys, Frantisek
Vymazal, Josef
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2012, 10
[30] Effectiveness and safety of tumor-treating fields therapy for glioblastoma: A single-center study in a Chinese cohort
She, Lei
Gong, Xuan
Su, Lin
Liu, Chao
FRONTIERS IN NEUROLOGY, 2023, 13

← 1 2 3 4 5 →